Close Menu

limited side effects

Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation

Issue: 
DOI: 
10.7727/wimj.2014.068
Pages: 
785–7
 
INTRODUCTION
 
Maraviroc, originally designated UK-427857, is a small molecule and the first oral antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. This drug, classed as an entry inhibitor, was developed by the drug company Pfizer in its United Kingdom laboratory located in Sandwich. 
 
Accepted: 
27 Mar, 2014
PDF Attachment: 
Journal Sections: 
e-Published: 29 Aug, 2014
Subscribe to RSS - limited side effects
Top of Page